# Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine

> **NCT02489929** · NA · UNKNOWN · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 35 (estimated)

## Conditions studied

- Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **OTHER:** blood samples
- **DRUG:** azacytidine

## Key facts

- **NCT ID:** NCT02489929
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2018-08
- **Final completion:** 2019-03
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2015-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02489929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02489929, "Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02489929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*